Stock Analysis

2seventy bio Full Year 2022 Earnings: Beats Expectations

Source: Shutterstock

2seventy bio (NASDAQ:TSVT) Full Year 2022 Results

Key Financial Results

  • Revenue: US$91.5m (up 68% from FY 2021).
  • Net loss: US$254.2m (loss narrowed by 13% from FY 2021).
  • US$7.13 loss per share (improved from US$12.44 loss in FY 2021).
NasdaqGS:TSVT Earnings and Revenue Growth March 18th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

2seventy bio Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 84%. Earnings per share (EPS) also surpassed analyst estimates by 14%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 1.8% from a week ago.

Risk Analysis

You should learn about the 5 warning signs we've spotted with 2seventy bio (including 2 which are a bit concerning).

Valuation is complex, but we're helping make it simple.

Find out whether 2seventy bio is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis